Clinical trial
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m…
NCT00317109 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00317109 |
|---|---|
| Title | Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects |
| Official title | Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Tritanrix™- HepB, Hiberix™, Mencevax™ ACW |
| Enrollment | 168 |
| Start date | Apr 19, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 17, 2007 |
| First posted | Apr 24, 2006 |
| Last update posted | Jun 6, 2018 |
| Countries | South Africa |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: